TrialInternational journal of surgery (London, England)2026

Efficacy and safety of neoadjuvant treatment of trastuzumab and pyrotinib plus dalpiciclib in HR-negative/HER2-positive breast cancer: an exploratory, open-label phase II study.

Zhi Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.